Job Listings


Here are our current job openings. Please click on the job title for more information, and apply from that page if you are interested.

Use this form to perform another job search

The system cannot access your location for 1 of 2 reasons:
  1. Permission to access your location has been denied. Please reload the page and allow the browser to access your location information.
  2. Your location information has yet to be received. Please wait a moment then hit [Search] again.


Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of our Translational Science Platform, we first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. Jounce was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. In July 2016, Jounce announced a global strategic collaboration with Celgene Corporation. This global strategic collaboration, which included a $225.0 million upfront payment and a $36.1 million equity investment, is primarily focused on co developing and co commercializing innovative biologic immunotherapy treatments for patients with cancer.

Jounce is an equal employment opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law.

All applicants should be legally entitled to work for any employer in the U.S.

Note to Employment Agencies: Please do not forward any agency resumes. The company will not be responsible for any fees related to resumes that are unsolicited.
Click column header to sort

Search Results

The IT and Informatics group at Jounce Therapeutics is looking for a seasoned Senior Infrastructure and Security Engineer to join the Jounce IT team. This role will be responsible for the day to day management of the Jounce IT infrastructure and security systems. They will be responsible for the identification, investigation, interpreting and remediating security vulnerabilities / breaches detected by the security and infrastructure management systems. Working closely with the Information Technology Manager on variety infrastructure and security driven initiatives. This is an exciting position in the dynamic field of immuno-oncology which provides opportunity for growth in a fast-paced, start-up environment.

 

Job ID
2017-1109
US-MA-Cambridge

This is an exciting opportunity to join the IT and Informatics professionals in a rapidly growing immunotherapy company while contributing to the discovery and development of novel therapeutics for cancer patients.  You will work closely with scientific project teams within Jounce and develop deep knowledge of immunotherapy programs.

 

As part of the the Research Informatics team, you will work closely with IT, Lab Operations, and R&D project teams.  The candidate will be responsible for the development and support of information systems and processes related to

  • tissue banking & imaging
  • histoculture and immunohistochemistry
  • genomics and RNA sequencing data

As a member of this team, the candidate will contribute to the design and evolution of informatics systems used by Jounce researchers.  They will also provide continuous support and coordinate changes to these systems.

 

This is an excellent opportunity to shape the future of the entire R&D division and lay the groundwork for an integrated scientific data platform.

 

Job ID
2017-1108
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

 

The Business Development Director will drive Jounce’s business development activities, support the BD strategy, and alliance management functions.  In this newly created position you will play a key role in leading a range of business development transactional activities at Jounce.  This highly visible position reports to the Chief Business Officer.  If you thrive in a fast-paced, high science culture, this is an outstanding opportunity for you

Job ID
2017-1107
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

 

The successful candidate for this CTA position will assist with daily clinical trial execution activities and assist in the coordination of documentation associated with the conduct of investigational clinical studies in accordance with FDA regulations, Good Clinical Practice (GCP), and company standard operating policies and procedures.

Job ID
2017-1106
US-MA-Cambridge

The Protein Science group at Jounce Therapeutics is looking for an individual experienced in antibody and protein characterization.  The successful candidate will play an important role in the discovery and development of novel biotherapeutics for immuno-oncology.  S/he will be responsible for screening and characterizing therapeutic antibodies using biochemistry, cell biology, and molecular biology techniques.  S/he will have the opportunity to work cross-functionally as part of internal multi-disciplinary program teams, and will take a lead role in experimental design and planning, conducting experiments, and communicating results.

Job ID
2017-1105
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

Job ID
2017-1103
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

 

Job ID
2017-1101
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

Job ID
2017-1100
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

Job ID
2017-1099
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

Job ID
2017-1094
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.

Job ID
2017-1093
US-MA-Cambridge

Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. 

Job ID
2017-1060
US-MA-Cambridge